Ocugen Wins Bahamian Nod for OCU400 as Dilution Vote Looms in October

Ocugen gained Bahamas provisional approval for OCU400, but no major regulatory milestones are expected before 2027 as dilution concerns weigh.

Ocugen's gene therapy ambitions just picked up an offshore regulatory tailwind — and a reminder of how far the balance sheet still has to stretch.

The US biotech secured provisional approval and priority status from the Bahamas' LARTA board for OCU400, its candidate treatment for the inherited eye disease retinitis pigmentosa. The designation opens the door to an Expanded Access Program on the island nation, with Ocugen aiming to treat the first patient within 90 days of receiving full LARTA authorization. The arrangement would let patients access the therapy well before any conventional market approval.

Shares traded in Europe edged up 1.2% to EUR 0.9040 on the news.

A Three-Application Blueprint Stretching to 2028

The Bahamian clearance sits alongside a broader clinical timetable that management has mapped out across three separate US license filings. OCU400 is slated to lead the sequence, with pivotal Phase 3 top-line data expected in the first quarter of 2027. That readout would underpin a filing with the FDA in the second quarter of 2027.

Next in line is OCU410ST for Stargardt disease, where fresh study results are also anticipated in the second quarter of 2027. The third leg — OCU410 for geographic atrophy tied to dry age-related macular degeneration — began its Phase 3 ArMaDa3 trial roughly two weeks ago, with final data targeted for the second half of 2028 and a regulatory submission toward the end of that year.

Beyond North America, Ocugen is in licensing discussions covering the Middle East and North Africa.

The practical takeaway for shareholders: no market-moving regulatory milestones are expected before 2027.

Cash Runway Versus the Cost of Waiting

Ocugen ended the second quarter with USD 100.1 million in cash, a reserve management says will fund operations into 2028 — enough, on paper, to carry the pipeline through its near-term catalysts.

The market, however, is focused on what happens before those catalysts arrive. A management proposal to increase authorized common stock by 250,000,000 shares drew a lukewarm reception and failed to win the necessary support, forcing a special meeting to be adjourned to October 5, 2026. Investors tend to react poorly to such expansion plans, which signal substantial future dilution.

Adding to the unease, CEO Shankar Musunuri sold 525,991 shares through a pre-arranged trading plan, raising roughly USD 589,109. Such transactions follow fixed rules, but they land awkwardly with the shareholder base during periods of strategic uncertainty.

A Stock That Has Already Priced In the Doubts

The gap between Ocugen's scientific aspirations and its financial reality is visible in the share price. The stock has been under pressure for much of the year, with losses since January ranging between 28% and 31% depending on the trading venue.

The market is no longer valuing the gene therapy portfolio on its potential alone — it is increasingly weighing the prospect of a financing overhang. October's vote will reveal how much latitude shareholders are still willing to grant management as it seeks fresh capital. Without secured funding, even the most promising clinical timelines through 2028 lose their shine.